Stored Cannabinoid Urine Screens Lost Signal Without Measuring Chemical Degradation
A stored urine specimen can lose cannabinoid screening response, but the response alone does not reveal exactly how much of a named compound chemically degraded. An analog-stability study used immunoassay signal as its endpoint rather than compound-specific mass-spectrometric concentrations.
The experiment used fortified human urine
Researchers added individual cannabinoid analogs or metabolites to pooled drug-free urine. The preparations were adjusted to pH 4.5, 7 or 9 and stored at 4°C, 20°C or 45°C. Each condition was prepared in triplicate.
Testing used one Lin-Zhi cannabinoid enzyme immunoassay configured at a 25 ng/mL cutoff. Each compound was initially fortified at twice its previously determined assay decision point. Those starting concentrations were compound-specific; the experiment did not simply add every analyte at 50 ng/mL.
Temperature, pH and target mattered
Parent-analog responses became undetectable after one day at 45°C across the tested pH conditions. Carboxylated analog responses generally fell more under acidic conditions than at neutral or alkaline pH. Some refrigerated responses declined initially and then showed little further decrease over the observation period.
The study included delta-8 THC and selected metabolites, delta-10-related isomers and carboxy-HHC stereoisomers. It did not establish a single universal loss rate for all cannabinoids, every assay manufacturer or authentic specimens from people using these products.
An antibody response is an operational measurement
An immunoassay responds according to antibody recognition and calibration. Its declining output establishes reduced response under that workflow. Without a parallel compound-specific concentration measurement, it cannot distinguish precise parent loss from every possible change in recognition, transformation products or other analytical behavior.
The practical concern is a specimen crossing the screening decision boundary after storage. This does not provide a numerical correction for a historical result or a method for estimating how much drug a person used. Case review should retain transport temperature, elapsed time, pH, the exact assay and the confirmatory procedure. Screening stability addresses analytical detection, not impairment.
Related: interpreting THC concentrations separately from impairment.
Primary research
The preanalytical stability of emerging cannabinoid analogs (delta-8 THC and its metabolites, delta-10 THC and carboxy-HHC) in urine. DOI: 10.1093/jat/bkad061.
